Proton-pump inhibitor prophylaxis in the ICU – benefits worth the risks? N Engl J Med 2018; 379: 2263-2264. Koop H, Fuchs KH, Labenz J et al.: S2k-Leitlinie: Gastroösophageale Refluxkrankkheit unter Federführung
cardiovascular events: what matters most: the drug, the dose, or the placebo? JAMA 2020; 324: 2262-2264. Budoff MJ, Bhatt DL, Kinninger A et al.: Effect of icosapent ethyl on progression of coronary at
dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38: 2264-2276. 95. Amarenco P, Kim JS, Labreuche J et al.: A comparison of two LDL cholesterol targets after
